Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of 14028 vs Dulaglutide in Healthy Subjects
NCT05459285Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum (peak) plasma drug concentration and Area under the plasma concentration-time curve from time zero to infinity. Started May 2022; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05459285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459285.